NOVO NORDISK A S (NVO)
About NOVO NORDISK A S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Market cap
- $215.7B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $215.7B
- Dividend yield
- 2.5%
- Shares outstanding
- 4.7B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 30, 1981
Novo Nordisk A S (NVO) Stock Price
- Trading 35% below its 52-week high.
- Pays a dividend yielding about 2.5% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NOVO NORDISK A S.
Write a review
News about NOVO NORDISK A S
News & sentiment via Polygon.io
Novo Nordisk A S: frequently asked questions
Is Novo Nordisk A S an American company?
Novo Nordisk A S is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Novo Nordisk A S publicly traded?
Yes — Novo Nordisk A S is a publicly traded company. Its stock trades under the ticker symbol NVO on the NYSE.
What does Novo Nordisk A S do?
Novo Nordisk A S is an American Pharmaceuticals company in the Health & Beauty sector.
